Pharmaceutical firms ramp up U.S. output amid tariff risk
Global drugmakers are boosting U.S. manufacturing to avoid 100 percent tariffs. Major firms have pledged billions to expand domestic research and production.
Global drugmakers are pledging more than $500B in United States investments to avoid 100% tariffs on branded medicines. The moves follow a Trump administration policy targeting foreign-made drugs unless companies lower prices or build domestic plants. For investors, these capital outlays aim to protect U.S. margins and secure long-term supply chain stability.
### Pfizer and AbbVie Lead Domestic Commitments PFIZER INC reached a deal on September 30 to invest $70B in research and domestic manufacturing. This agreement secured a three-year grace period exempting its products from pharmaceutical-targeted tariffs. ABBVIE INC committed $100B over the next decade for U.S. research as part of a three-year deal to reduce drug prices.
